Heparin Léčiva

Heparin Sodium, the active ingredient in Heparin Léčiva, is an anticoagulant presented as an injectable solution for intravenous use. It is employed to prevent and treat thromboembolic disorders in patients at risk of clot formation, such as those undergoing surgery, immobilization, or with a history of venous thromboembolism, and is widely used in clinical practice.

GNH USA supplies Heparin Léčiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation through global distribution channels.

Heparin Léčiva is used in the anticoagulation pathway to manage and prevent thromboembolic conditions. - Prevention of venous thromboembolism: reduces incidence of deep‑vein thrombosis and pulmonary embolism in at‑risk patients. - Treatment of acute thromboembolism: facilitates clot resolution and prevents propagation of existing clots. - Cardiopulmonary bypass anticoagulation: maintains circuit patency during cardiac and vascular surgery.

Heparin Léčiva may cause a range of adverse reactions.

Common Side Effects: - Bleeding: excessive or unexpected hemorrhage at surgical sites or mucosal surfaces. - Thrombocytopenia: reduction in platelet count, often mild and transient. - Injection site reactions: pain, erythema, or bruising at the intravenous access point. - Elevated liver enzymes: transient increases in hepatic transaminases. - Hyperkalemia: occasional rise in serum potassium levels.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia type II: immune‑mediated platelet activation leading to paradoxical clotting. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Anaphylaxis: severe allergic reaction with hypotension, urticaria, and airway compromise. - Osteoporotic fractures: decreased bone density with prolonged high‑dose therapy.

Before using Heparin Léčiva, consider the following safety measures. - Renal impairment: monitor anti‑Xa levels and adjust dosing as clearance may be reduced. - Hepatic disease: observe coagulation parameters closely due to altered metabolism. - Recent surgery or trauma: heightened risk of bleeding; evaluate hemostasis before administration. - Concomitant anticoagulants: avoid additive anticoagulant effects that can cause severe hemorrhage. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Heparin Léčiva can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Warfarin: additive anticoagulant effect leading to severe bleeding. - Direct oral anticoagulants (e.g., dabigatran, rivaroxaban): increased risk of hemorrhage. - Thrombolytic agents (e.g., alteplase): synergistic bleeding potential. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened hemorrhage risk.

Moderate Interactions (Monitor Closely): - Heparin‑binding proteins (e.g., lipoprotein(a)): may reduce anticoagulant efficacy. - Antiplatelet agents (e.g., clopidogrel): monitor for additive bleeding. - ACE inhibitors: rare potentiation of hypotension when combined with heparin.